| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| P50 | author | Cam Donaldson | Q17305874 |
| Anthony Harris | Q51541466 | ||
| Don Husereau | Q39190051 | ||
| Diane Lorenzetti | Q39273856 | ||
| P2093 | author name string | Braden Manns | |
| Fiona Clement | |||
| Scott Klarenbach | |||
| Marja Blom | |||
| Lianne Barnieh | |||
| P2860 | cites work | Pharmaceutical policies: effects of cap and co-payment on rational drug use | Q24242490 |
| The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis | Q28469242 | ||
| Determinants of generic drug substitution in Switzerland | Q33804307 | ||
| Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications | Q34001878 | ||
| The Netherlands: health system review | Q34153464 | ||
| Pharmacoeconomics: NICE's approach to decision-making | Q34174867 | ||
| Pharmaceutical policies in European countries in response to the global financial crisis. | Q34307945 | ||
| European healthcare policies for controlling drug expenditure | Q35039878 | ||
| Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? | Q36169463 | ||
| Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010 | Q36179271 | ||
| An attempt to save money by using mandatory practice guidelines in France | Q36246690 | ||
| Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures | Q36432075 | ||
| Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma | Q36543510 | ||
| Prescription drug cost sharing: associations with medication and medical utilization and spending and health. | Q36869615 | ||
| Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? | Q82283117 | ||
| The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary | Q82564188 | ||
| Health technology assessment in Canada: 20 years strong? | Q84065625 | ||
| Health technology assessment: a perspective from Germany | Q84065630 | ||
| The impact of copayments and safety nets on PBS expenditure | Q84139689 | ||
| How New Zealand has contained expenditure on drugs | Q84255946 | ||
| Recent developments in pharmacoeconomic evaluation in Ireland | Q84399540 | ||
| Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden. | Q51102839 | ||
| Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan. | Q51752423 | ||
| Institute for Quality and Efficiency in Health Care: Germany. | Q51817661 | ||
| Does free care improve adults' health? Results from a randomized controlled trial. | Q52699393 | ||
| Full Coverage for Preventive Medications after Myocardial Infarction | Q56872760 | ||
| The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries | Q57227437 | ||
| National Drug Policies to Local Formulary Decisions in Thailand, China, and Australia: Drug Listing Changes and Opportunities | Q57574281 | ||
| FROM CLINICAL RECOMMENDATIONS TO MANDATORY PRACTICE The Introduction of Regulatory Practice Guidelines in the French Healthcare System | Q57780099 | ||
| Current National Initiatives and Policies to Control Drug Costs in Europe | Q58817875 | ||
| Setting priorities for the adoption of health technologies on a national level -- the Israeli experience | Q73389214 | ||
| Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis | Q79381633 | ||
| Impact of statin copayments on adherence and medical care utilization and expenditures | Q79437194 | ||
| Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand | Q80515645 | ||
| Pricing and reimbursement of pharmaceuticals in Italy | Q81487104 | ||
| Procedures and methods of benefit assessments for medicines in Germany. | Q37318854 | ||
| Medicare Part D-a roundtable discussion of current issues and trends | Q37363162 | ||
| Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. | Q37365655 | ||
| Cost sharing and the initiation of drug therapy for the chronically ill. | Q37419499 | ||
| Austria: history of health technology assessment during the past 20 years | Q37509242 | ||
| The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair? | Q37556655 | ||
| Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence. | Q37565398 | ||
| Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests | Q37629903 | ||
| Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer | Q37655267 | ||
| Ongoing pharmaceutical reforms in France: implications for key stakeholder groups | Q37663648 | ||
| Recent developments in pricing and reimbursement of medicines in Ireland | Q37763119 | ||
| Evidence-based decision-making on medical technologies in China, Japan, and Singapore | Q37768540 | ||
| Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea | Q37768543 | ||
| Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan | Q37768545 | ||
| Evaluation on the first 2 years of the positive list system in South Korea | Q37946068 | ||
| Health economics and health technology assessment: perspectives from Australia and New Zealand | Q37962093 | ||
| Insight into recent reforms and initiatives in Austria: implications for key stakeholders | Q40065004 | ||
| Adverse events associated with prescription drug cost-sharing among poor and elderly persons | Q42644645 | ||
| Public drug expenditure in the Republic of Ireland | Q42663947 | ||
| Employer drug benefit plans and spending on prescription drugs | Q42684954 | ||
| Acceptable Incremental Cost Effectiveness Ratio for Use of New Drugs, Cases in Statin Therapies | Q42866617 | ||
| Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly | Q44333132 | ||
| Pharmacy benefit caps and the chronically ill. | Q45945467 | ||
| The impact of co-payment increases on dispensings of government-subsidised medicines in Australia | Q46304095 | ||
| Evidence-based decision-making within Australia's pharmaceutical benefits scheme | Q49110619 | ||
| National Authority for Health: France. | Q49110656 | ||
| Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. | Q50118718 | ||
| Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance | Q50138094 | ||
| Drug reimbursement decision-making in Thailand, China, and South Korea | Q50145677 | ||
| Pharmaceutical pricing and reimbursement reforms in Greece | Q50151017 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| pharmaceutical preparation | Q66089252 | ||
| P304 | page(s) | e90434 | |
| P577 | publication date | 2014-01-01 | |
| 2014-03-11 | |||
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development | |
| P478 | volume | 9 |
| Q27301465 | Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2×2 factorial randomized trial |
| Q36068256 | Catastrophic Health Care Expenditure among Older People with Chronic Diseases in 15 European Countries |
| Q93005988 | Co-payment for Unfunded Additional Care in Publicly Funded Healthcare Systems: Ethical Issues |
| Q36743290 | Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly |
| Q47406180 | Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs |
| Q37627254 | Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. |
| Q55101483 | Drug coverage in Canada: gaps and opportunities. |
| Q38689751 | Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. |
| Q58804318 | Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D |
| Q55359165 | Regulating pharmaceutical companies' financial largesse. |
| Q92218677 | The Economic Burden of Breast Cancer Survivors in Korea: A Descriptive Study Using a 26-Month Micro-Costing Cohort Approach |
| Q28069734 | Universal prescription drug coverage in Canada: Long-promised yet undelivered |
| Q38357567 | Value-based health care for inflammatory bowel diseases |
Search more.